Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will set a target date for the implementation of a nationwide prostate cancer screening programme for men with a BRCA variant.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care will consider the final recommendation of the UK National Screening Committee (UK NSC) on screening for prostate cancer when it is received. He will make a decision on implementation, including any timeline, at that point.
It is anticipated that the final recommendation will be provided in early 2026 after the conclusion of a 12 week consultation which opened on 28 November 2025. This seeks views on an evidence review and a draft recommendation to:
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessments his department has made of the predicted total cost of UK-US pharmaceutical deal on the NHS budget.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will provide guidance, resources, and risk assessment tools to general practitioners to support discussions with patients eligible for targeted prostate cancer screening.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his policy to expand BRCA testing to men, including those with male relatives of confirmed BRCA carriers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how he plans to fund the UK-US pharmaceutical deal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to leverage emerging technologies to combat falsified medicines and improve patient safety.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment of the impact of the disapplication of the EU Falsified Medicines Directive (EU FMD) on the United Kingdom’s medicine supply chain has been made by the Department. However, the Medicines and Healthcare products Regulatory Agency (MHRA) is not aware of any falsified medicines reaching patients through the legal supply chain in at least the last five years.
The MHRA leads work to combat falsified medicines and protect patient safety, including through the application of the Human Medicines Regulations 2012 to online and retail sales. The MHRA uses several different approaches to support its work to combat falsified medicines entering the UK supply chain, including by leveraging emerging technology, for instance:
Any additional initiatives to use emerging technologies, such as smartphone verification scanning, would require careful consideration of the evidence of the reduction of the risk to patients, as well as investment needed for infrastructure, and further regulatory changes for manufacturers and wholesalers. There are provisions in the Medicines and Medical Devices Act 2021 providing powers to enable the introduction of a similar system to the EU FMD with ‘safety features’ and verification in the UK. However, the powers allow us to go beyond the EU FMD and use derived data from any system for other health related purposes. For example, to support the recall of medicines, to support patient care, research, policy development, medicine supply, preventing diversion, supporting patient access to medicines, and countering fraud in primary care. However, regulations would be needed to set out the detail of any scheme, which would require consultation. Consideration is being given as to whether to consult on options for a potential UK system.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of the disapplication of the EU Falsified Medicines Directive on the UK’s medicine supply chain.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment of the impact of the disapplication of the EU Falsified Medicines Directive (EU FMD) on the United Kingdom’s medicine supply chain has been made by the Department. However, the Medicines and Healthcare products Regulatory Agency (MHRA) is not aware of any falsified medicines reaching patients through the legal supply chain in at least the last five years.
The MHRA leads work to combat falsified medicines and protect patient safety, including through the application of the Human Medicines Regulations 2012 to online and retail sales. The MHRA uses several different approaches to support its work to combat falsified medicines entering the UK supply chain, including by leveraging emerging technology, for instance:
Any additional initiatives to use emerging technologies, such as smartphone verification scanning, would require careful consideration of the evidence of the reduction of the risk to patients, as well as investment needed for infrastructure, and further regulatory changes for manufacturers and wholesalers. There are provisions in the Medicines and Medical Devices Act 2021 providing powers to enable the introduction of a similar system to the EU FMD with ‘safety features’ and verification in the UK. However, the powers allow us to go beyond the EU FMD and use derived data from any system for other health related purposes. For example, to support the recall of medicines, to support patient care, research, policy development, medicine supply, preventing diversion, supporting patient access to medicines, and countering fraud in primary care. However, regulations would be needed to set out the detail of any scheme, which would require consultation. Consideration is being given as to whether to consult on options for a potential UK system.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the efficacy of smartphone-enabled barcode scanning in the verification of medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment of the impact of the disapplication of the EU Falsified Medicines Directive (EU FMD) on the United Kingdom’s medicine supply chain has been made by the Department. However, the Medicines and Healthcare products Regulatory Agency (MHRA) is not aware of any falsified medicines reaching patients through the legal supply chain in at least the last five years.
The MHRA leads work to combat falsified medicines and protect patient safety, including through the application of the Human Medicines Regulations 2012 to online and retail sales. The MHRA uses several different approaches to support its work to combat falsified medicines entering the UK supply chain, including by leveraging emerging technology, for instance:
Any additional initiatives to use emerging technologies, such as smartphone verification scanning, would require careful consideration of the evidence of the reduction of the risk to patients, as well as investment needed for infrastructure, and further regulatory changes for manufacturers and wholesalers. There are provisions in the Medicines and Medical Devices Act 2021 providing powers to enable the introduction of a similar system to the EU FMD with ‘safety features’ and verification in the UK. However, the powers allow us to go beyond the EU FMD and use derived data from any system for other health related purposes. For example, to support the recall of medicines, to support patient care, research, policy development, medicine supply, preventing diversion, supporting patient access to medicines, and countering fraud in primary care. However, regulations would be needed to set out the detail of any scheme, which would require consultation. Consideration is being given as to whether to consult on options for a potential UK system.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department for Transport:
To ask the Secretary of State for Transport, pursuant to the Answer of 3 November 2025 to Question 86345 on Whitchurch Station: Access, if she will announce the timeline for completion of Access for All construction at Whitchurch Railway Station.
Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport)
We are committed to improving the accessibility of the railway and recognise the social and economic benefits this brings to communities.
Since 2006 the Access for All programme has installed accessible, step free routes at over 270 stations plus a range of smaller scale access improvements at around 1500 stations.
In May 2024, the previous government published a list of 50 additional stations selected for initial feasibility work, which included Whitchurch railway station.
Network Rail have now completed all 50 feasibility studies and we will shortly be announcing which of those stations will progress.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department for Transport:
To ask the Secretary of State for Transport, pursuant to the Answer of 3 November 2025 to Question 86345 on Whitchurch Station: Access, when she plans to announce her Department’s decision regarding the stations selected for Access for All funding.
Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport)
We are committed to improving the accessibility of the railway and recognise the social and economic benefits this brings to communities.
Since 2006 the Access for All programme has installed accessible, step free routes at over 270 stations plus a range of smaller scale access improvements at around 1500 stations.
In May 2024, the previous government published a list of 50 additional stations selected for initial feasibility work.
Network Rail have now completed all 50 feasibility studies and we will shortly be announcing which of those stations will progress.